Pauci-immune Glomerulonephritis Treatment Market to Expand at a CAGR of 4.2% during 2023-2031, Says Growth Plus Reports


Newark, New Castle, USA, May 31, 2023 (GLOBE NEWSWIRE) — The market analysis of the global pauci-immune glomerulonephritis treatment market was conducted by Growth Plus Reports in 2022. The market is expected to hit a revenue CAGR of 4.2% by 2031. According to a recent market research analysis released by Growth Plus Reports, the worldwide Pauci-immune Glomerulonephritis (PIGN) therapy market is anticipated to have rapid expansion in the years to come. The report highlights key trends, market drivers, challenges, and opportunities that will shape the industry landscape.

Pauci-immune Glomerulonephritis is a rare autoimmune kidney disease identified by inflammation of the small blood vessels in the kidneys. A potentially severe condition can lead to kidney failure if left untreated. With an increasing incidence of PIGN cases worldwide, there is a rising demand for effective treatment to address this unmet medical need.

Request a Sample Copy of the Research Report:


                     Pauci-immune Glomerulonephritis Treatment Market Scope

Report Attribute Details
CAGR 4.2%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Treatment, Distribution Channel, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The market report reveals that the Pauci-immune Glomerulonephritis treatment market is expected to experience exponential growth over the forecast period. Factors like the rising prevalence of autoimmune disorders, advancements in diagnostic techniques, and the introduction of novel therapeutics are fueling the market growth.

One of the key drivers for market expansion is the increasing adoption of biologic drugs for PIGN treatment. Biologic drugs offer targeted and precise mechanisms of action, which are particularly beneficial for autoimmune diseases like PIGN. Moreover, ongoing research and development activities are focused on identifying new drug targets and innovative therapeutic approaches, which are expected to boost the market further.

However, despite the promising growth prospects, the market faces challenges that must be addressed. High treatment costs, limited awareness among patients and healthcare professionals, and stringent regulatory requirements are key hurdles. Efforts to improve patient education, increase disease awareness, and establish reimbursement policies are crucial to overcome these challenges.

Market Segmentation: 

  • Based on Treatment, the global Pauci-immune Glomerulonephritis Treatment Market is segmented into Immunosuppressive Therapy, Inductive Therapy, and Others. 
  • Based on Distribution Channel, the global Pauci-immune Glomerulonephritis Treatment Market is segmented into Hospital, Retail, and Online Pharmacies. 

Additionally, the report highlights the significant role of collaborations and partnerships among pharmaceutical companies, research institutions, and regulatory bodies in advancing PIGN treatment options. Such collaborations facilitate the exchange of knowledge and resources, expediting the drug development process and ensuring timely regulatory approvals.

Request for Customization –

Geographically, North America currently dominates the global PIGN treatment market, owing to well-established healthcare infrastructure, high R&D investments, and favorable reimbursement policies. However, Asia Pacific is expected to register a substantial revenue growth rate during the forecast period, driven by the increasing patient pool, improving healthcare infrastructure, and rising healthcare expenditure.

The key market players operating in the Pauci-immune Glomerulonephritis treatment market are: 

  • Merck & Co., Inc.
  • Novartis AG
  • Genentech, Inc.
  • Pfizer Inc.
  • Bristol Myers Squibb Company

These companies focus on strategic initiatives such as product launches, collaborations, acquisitions, and partnerships to strengthen their position in the market and expand their product portfolios.

In conclusion, the global Pauci-immune Glomerulonephritis treatment market will grow significantly in the coming years. Advancements in biological drugs, increasing research activities, and collaborative efforts drive market expansion. However, challenges such as high treatment costs and limited awareness must be addressed to ensure optimal patient outcomes. With the right strategies and investments, stakeholders in the PIGN treatment market can make a substantial impact in improving patients’ lives worldwide.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursement Scenario 
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Immunosuppressive Therapy
    2. Inductive Therapy
    3. Others
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies


Buy this Premium Research Report:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst:

Visit our report store at –

Browse more latest healthcare reports:

Medical Device Analytical Testing Outsourcing Market by Service (Material Characterization, Extractable and Leachable), Application (Cardiology, Diabetes Care), End User (Hospitals, Homecare Setting)– Global Outlook & Forecast 2023-2031

Differentiated Thyroid Cancer Therapeutics Market by Therapy (Thyroid Stimulating Hormone Suppression, Chemotherapy), End User (Hospitals, Oncology Centers) – Global Outlook & Forecast 2023-2031

Medicated Feed Additives Market by Animal Type (Ruminants, Swine, Poultry), Type (Antibiotics, Vitamins, Antioxidants), Mixture Type (Supplements, Concentrates)– Global Outlook & Forecast 2023-2031

Rare Neurological Disease Treatment Market by Drug Type (Biologics, Small Molecules), Indication (Narcolepsy, Creutzfeldt-Jakob Disease, Multiple Sclerosis), Distribution Channel (Hospital Pharmacies, Retail Pharmacies)– Global Outlook & Forecast 2023-2031

Phototherapy Lamps and Units for Aesthetic Medicine Market by Modality (Fixed Units, Mobile Units), Source (Infrared Light, UV Light), End User (Skincare & Cosmetic Clinics, Hospitals)– Global Outlook & Forecast 2023-2031

Unleashing the Power of Innovation in Med Tech

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.